Matthew Weston
Stock Analyst at UBS
(2.55)
# 2,302
Out of 5,090 analysts
5
Total ratings
100%
Success rate
12.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DBX Dropbox | Assumes: Sell | $29 → $27 | $29.34 | -7.98% | 1 | Sep 18, 2025 | |
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $47.86 | - | 1 | Aug 5, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $132.16 | - | 1 | Feb 13, 2025 | |
| AZN AstraZeneca | Upgrades: Buy | n/a | $90.18 | - | 2 | Feb 13, 2025 |
Dropbox
Sep 18, 2025
Assumes: Sell
Price Target: $29 → $27
Current: $29.34
Upside: -7.98%
Novo Nordisk
Aug 5, 2025
Downgrades: Neutral
Price Target: n/a
Current: $47.86
Upside: -
Novartis AG
Feb 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $132.16
Upside: -
AstraZeneca
Feb 13, 2025
Upgrades: Buy
Price Target: n/a
Current: $90.18
Upside: -